Current news of SHS and our portfolio companies

14 January 2021 - SHS News

Medtech investor SHS sold shares in Single Use Support GmbH

SHS Gesellschaft für Beteiligungsmanagement mbH (SHS) has sold its shares in the Austrian life science supplier Single Use Support GmbH (SUS) to Pall Corporation. SUS sets new standards for the transport of liquid substances in the medtech industry with its products, a success story Life science, biotech, pharmaceutical and medical device companies worldwide now use […]

12 January 2021 - Portfolio News, SHS News

SHS is investing in Blue Ocean Spine, a medtech firm based in Tuttlingen, Germany, and specializing in functional spinal implants

The Tübingen-based medtech investor SHS is investing in Blue Ocean Spine GmbH, a developer for 3D-printed spinal implants Blue Ocean Spine is developing a portfolio of new spinal implants that can be precisely adapted to patient needs in situ or administered without additional means of fixation such as screws For Guntmar Eisen, a serial entrepreneur […]

7 January 2021 - Press Releases

medtech-INSIDE – financial column, part 3: “Medtech in transition: Approval procedures in China”

With a population of around 1.4 billion, the People’s Republic of China is an enormously attractive market for medtech and life-science products. For foreign firms, this presents not only great opportunities but risks as well. By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector […]

29 December 2020 - Press Releases

ZDF heute Sendung: “New rapid test from Bavaria”

ZDF TV reports in its heute Sendung (from min. 07:32) at prime time about our portfolio company GNA Biosolutions GmbH. The company has received emergency approval for its point-of-care test, which enables detection for COVID19 within 40 minutes.

29 December 2020 - Portfolio News

GNA Biosolutions Receives Emergency Use Authorization from German Health Authority BfArM for Rapid Molecular SARS-CoV-2 Batch Testing System

German molecular diagnostics startup GNA Biosolutions has received Emergency Use Authorization (Sonderzulassung) from the German Federal Institute for Drugs and Medical Devices (BfArM) for the GNA Octea SARS-CoV-2 Test System. The new technology developed by GNA Biosolutions enables decentralized COVID-19 rapid tests in approximately 40 minutes without sacrificing sensitivity.

19 December 2020 - Press Releases

Badische Zeitung: “SHS invests in Develco”

The Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH invests from its SHS V fund in the Swiss-German specialty pharmaceuticals company Develco Pharma.

18 December 2020 - Social Projects

With our annual project 2020 we are supporting the “Minilab Project”, an initiative of the Tübingen institute “Difäm – Deutsches Institut für Ärztliche Mission e.V” (German Institute for Medical Mission)

Every year, counterfeit medicines cause harm to many patients, particularly in developing countries. This problem is being tackled by a joint project of the Tübingen-based Difäm and the Ecumenical Pharmaceutical Network (EPN) that aims to detect counterfeit medicines in developing countries with the help of local analytics. To this end, local centres are provided with […]

17 December 2020 - Portfolio News

Multi-million order for Graz-based medtech company Tyromotion

Positive economic news is rare in times of crisis. This makes this news from Graz all the more pleasing: an order worth millions of euros gives SHS portfolio company Tyromotion a positive outlook for the future.

17 December 2020 - SHS News

SHS invests in Swiss-German specialty drug company Develco Pharma

Tübingen-based industry investor SHS acquires minority share in formulation specialist Develco Pharma Develco specializes in the development, approval and production of innovative and generic specialty drugs and offers a unique and broad set of formulation technologies for orally administered medicines with specific substance-release profiles Develco operates a state-of-the-art production facility of its own in Germany […]

3 December 2020 - Press Releases

medtech-INSIDE – financial column, part 2: “Fast-track approval and reimbursement in the US: the Breakthrough Devices Program”

While the EU is significantly raising approval hurdles with the MDR, the US is putting medtech innovations in the fast lane with the Breakthrough Devices Program By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector as a business development expert. Putting the brakes on […]